Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development
Horsham, PA, (Vocus) July 30, 2009
The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.
The workshop will examine evolving scientific data surrounding CV safety and diabetic drug development, future methods to make development of these drugs more streamlined while ensuring safety. Session topics will include:
Type 2 Diabetes: Clinical implications, CV manifestations, and epidemiology
Therapies and targets for treatment of Diabetes Mellitus – potential implications on CV safety
Glycemic control – evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM
New trial design approaches to assessing CV safety
Clinical evidence that T2DM diabetic drugs can increase CV risk
Diabetic drug development and CV safety
Approaches to clinical analysis of CV risk
Novel clinical trial approaches
Future approaches to assessing T2DM drug development and CV safety
QT experience as a model for furthering collaborative approaches/research in CV
“Recent data published in major medical journals suggests possible increase in cardiovascular (CV) risk associated with the use of certain drugs for the treatment of type 2 diabetes (T2DM),” explains Program Chair Philip T. Sager, MD, FACC, Vice President, Clinical Research, Cardiopulmonary and Metabolic Clinical Development, Gilead Sciences, Inc. “As a result, the Division of Metabolism and Endocrinology Products of the US Food and Drug Administration (FDA) issued a new guidance in December 2008 recommending that all new T2DM drugs demonstrate CV safety in appropriately designed and powered outcome studies.”
About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.
Contact:
Joe Krasowski
Drug Information Association
215-293-5812
http://www.diahome.org
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Keep ‘em coming… you all do such a great job at such Concepts… can’t tell you how much I, for one appreciate all you do!